On September 17, 2020 HiFiBiO Therapeutics reported that a novel approach for patient stratification demonstrating its proprietary Drug Intelligent Science (DIS) single-cell platform at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Tumor Heterogeneity Virtual Special Conference taking place today (Press release, HiFiBiO Therapeutics, SEP 17, 2020, View Source [SID1234565293]). The company is a pioneer of novel antibody drug discovery and development, leveraging single-cell analytics to treat cancer, autoimmune and infectious disorders. HiFiBiO invites members of the scientific and medical communities to listen to the poster presentation online at the AACR (Free AACR Whitepaper) meeting website or, after the AACR (Free AACR Whitepaper) meeting has concluded, on the HiFiBiO Therapeutics website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This presentation demonstrates the potential of our DIS single-cell platform to identify biomarkers that can predict if patients will respond to treatment," said Andreas Raue, PhD, Senior Director and Head of Drug Intelligent Science at HiFiBiO Therapeutics. "Given our depth of experience in immune modulation and single-cell science, we believe our DIS platform has the potential to transform how we mine immune biomarkers to identify the best immunotherapies for each and every patient."

Poster Presentation Details
Title: Single-cell immune profiling identifies signature that predicts PD-L1 blockade outcome
Presenter: Dean Lee, Scientist, Drug Intelligent Science at HiFiBiO Therapeutics
Poster: PO-048, Link to presentation